Skip to main content
    E

    Eton Pharmaceuticals Inc (ETON)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $63.88
    -0.05 (-0.08%)

    Market Cap: $1.84B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Eton Pharmaceuticals Inc (ETON) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Eton Pharmaceuticals reported revenue of $79.95M for the fiscal year ended Dec 31, 2025, up 104.9% from the year before. That year, net income was -$4.60M with a net margin of -5.8%, operating cash flow was $10.52M and free cash flow was $10.19M. The quarter ended Sep 30, 2026 had revenue of $57.92M and net income of $35.25M.

    Revenue and Margins

    The operating margin was -1.1% in the fiscal year ended Dec 2025, the highest of the 5 years shown with an operating margin. Over the 6 years to Dec 2025, revenue grew from $959.00K, a compound annual rate of 109.0%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$79.95M+104.9%53.5%-1.1%-5.8%
    Dec 2024$39.01M+23.3%60.0%-6.7%-9.8%
    Dec 2023$31.64M+48.9%66.6%-3.8%-3.0%
    Dec 2022$21.25M-2.7%67.4%-38.9%-42.4%
    Dec 2021$21.83M+55879.5%87.1%-6.8%-9.0%
    Dec 2020$39.00K-95.9%-1017.9%-69515.4%-71717.9%
    Dec 2019$959.00KN/A52.8%-1939.6%-1910.3%
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Revenue$79.95M$39.01M$31.64M$21.25M$21.83M$39.00K$959.00K$0$0
    Cost of revenue$37.21M$15.60M$10.58M$6.93M$2.83M$436.00K$453.00K$0$13.00K
    Gross profit$42.74M$23.41M$21.06M$14.32M$19.00M-$397.00K$506.00K$0-$13.00K
    Research and development$7.76M$3.25M$3.32M$4.00M$6.24M$14.10M$11.55M$5.63M$3.93M
    Operating income-$844.00K-$2.60M-$1.19M-$8.26M-$1.50M-$27.11M-$18.60M-$10.32M-$7.15M
    Net income-$4.60M-$3.82M-$936.00K-$9.02M-$1.96M-$27.97M-$18.32M-$12.74M-$7.16M
    EBITDA$182.00K-$1.55M$329.00K-$7.12MN/AN/A-$17.86MN/A-$7.14M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$57.92M$37.59M$24.27M$21.28M$22.46M$18.93M$17.28M$11.65M$10.32M$9.07M$7.97M$7.31M
    Gross profit$44.30M$25.41M$14.73M$13.10M$7.86M$11.92M$9.86M$6.48M$6.30M$5.63M$5.01M$3.63M
    Operating income$23.01M$12.79M$2.41M$2.46M-$1.36M-$1.48M-$470.00K$629.00K$509.00K-$2.94M-$800.00K-$1.99M
    Net income$35.25M$11.58M$1.55M$1.48M-$1.93M-$2.58M-$1.57M-$598.00K$627.00K-$3.04M-$811.00K-$2.26M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $30.56M exceeded cash and equivalents by $4.62M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$92.11M$76.12M$31.74M$25.03M$27.46M$26.32M$17.07M$28.33M$13.44M
    Current assets$60.58M$41.02M$26.84M$20.00M$23.60M$24.70M$15.01M$27.50M$13.29M
    Cash and equivalents$25.94M$14.94M$21.39M$16.30M$14.41M$21.30M$12.07M$26.73M$13.16M
    Total liabilities$65.96M$51.70M$16.26M$11.95M$9.84M$10.66M$6.52M$2.02M$1.31M
    Short-term debt$8.79M$0$5.38M$1.03M$1.42M$0$0$0$0
    Long-term debt$21.77M$29.81M$0$5.38M$5.26M$6.76M$4.54M$0$0
    Shareholder equity$26.15M$24.43M$15.48M$13.08M$17.63M$15.66M$10.55M$26.30M-$6.87M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$157.27M$115.81M$97.71M$92.11M$104.51M$101.68M$84.03M$76.12M$35.84M$31.82M$30.79M$31.74M
    Total liabilities$70.35M$69.22M$67.09M$65.96M$81.38M$77.72M$59.58M$51.70M$19.86M$18.36M$15.30M$16.26M
    Cash and equivalents$55.63M$26.84M$19.66M$25.94M$37.12M$25.38M$17.42M$14.94M$20.26M$17.69M$16.66M$21.39M
    Shareholder equity$86.92M$46.59M$30.61M$26.15M$23.13M$23.96M$24.45M$24.43M$15.98M$13.46M$15.49M$15.48M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 96.9% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow$10.52M$969.00K$6.82M$4.82M-$4.72M-$22.35M-$18.03M-$8.14M-$4.72M
    Capital expenditures$333.00K$26.00K$0$38.00K$9.00K$50.00K$1.10M$236.00K$130.00K
    Free cash flow$10.19M$943.00K$6.82M$4.78M-$4.73M-$22.40M-$19.12M-$8.38M-$4.85M
    Dividends paidN/AN/AN/AN/AN/AN/AN/A$1.05M$0
    Investing cash flow-$333.00K-$40.01M-$775.00K-$2.79M-$2.56M-$50.00K-$1.85M-$236.00K-$130.00K
    Financing cash flow$815.00K$32.59M-$957.00K-$134.00K$391.00K$31.63M$5.20M$21.96M$18.00M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$35.24M$7.25M$7.41M-$11.55M$12.03M$7.96M$2.09M-$765.00K$2.95M$1.25M-$2.47M$387.00K
    Capital expenditures$13.00K$5.00K$75.00K$49.00K$284.00K$0$0$12.00K$1.87M$0$14.00K$775.00K
    Free cash flow$35.23M$7.25M$7.33M-$11.60M$11.74M$7.96M$2.09M-$777.00K$1.08M$1.25M-$2.49M-$388.00K
    Last 12 quarters

    Frequently Asked Questions About ETON

    What is Eton Pharmaceuticals' annual revenue?

    Eton Pharmaceuticals reported revenue of $79.95M for the fiscal year ended Dec 31, 2025.

    How fast is Eton Pharmaceuticals' revenue growing?

    Revenue was up 104.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 55.5%.

    Is Eton Pharmaceuticals profitable?

    No. Eton Pharmaceuticals reported net income of -$4.60M for the fiscal year ended Dec 31, 2025, with a net margin of -5.8%.

    How much free cash flow does ETON generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $10.52M minus capital expenditures of $333.00K produced free cash flow of $10.19M.

    How much debt does Eton Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $21.77M, short-term debt of $8.79M and cash and equivalents of $25.94M.